Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T cell infiltration

PURPOSE: A phase I study was conducted to determine safety, clinical efficacy, and anti-tumor immune responses in patients with advanced non-small cell lung carcinoma (NSCLC) following intratumoral (IT) administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Lee, Jay M., Lee, Mi-Heon, Garon, Edward B., Goldman, Jonathan W., Salehi-Rad, Ramin, Baratelli, Felicita E., Schaue, Dörthe, Wang, Gerald, Rosen, Fran, Yanagawa, Jane, Walser, Tonya C., Lin, Ying, Park, Stacy J., Adams, Sharon, Marincola, Francesco M., Tumeh, Paul C., Abtin, Fereidoun, Suh, Robert, Reckamp, Karen L., Lee, Gina, Wallace, William D., Lee, Sarah, Zeng, Gang, Elashoff, David A., Sharma, Sherven, Dubinett, Steven M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599263/
https://ncbi.nlm.nih.gov/pubmed/28468947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2821
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak